FDA Approves New Interchangeable Biosimilar to Pertuzumab By Ogkologos - December 3, 2025 7 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ March 8, 2019 18-Year-Old Jaguar at Akron Zoo Diagnosed with Breast Cancer September 6, 2019 Finding Hope During Cancer and Pregnancy: “Your Stories” Podcast December 2, 2020 Breaking the silence: when cancer steals your voice December 2, 2022 Load more HOT NEWS Higher Risk of Heart Failure Seen in Some Cancers Antitumour Activity of Combination of Lenvatinib and Pembrolizumab in Patients with... Dabrafenib Plus Trametinib Improves Efficacy in Children and Adolescents with Relapsed/Refractory... FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer